Targeted alpha therapy (TAT) is a promising approach for the treatment of cancer. The use of alpha emitters for cancer therapy has two distinct advantages over conventional therapies. The short range of alpha radiation in human tissue (< 0.1 mm), corresponding to only a few cell diameters, allows selective killing of targeted cancer cells while sparing surrounding healthy tissue. At the same time, the high energy (several MeV) of alpha radiation and its associated high linear energy transfer leads to highly effective cell kill. Consequently, alpha radiation can destroy cells which otherwise exhibit resistance to treatment with beta or gamma irradiation or chemotherapeutic drugs, and can thus offer a therapeutic option for tumors resistant to conventional therapies. Recent results demonstrating the remarkable therapeutic efficacy of alpha emitters to treat various cancers have underlined the clinical potential of TAT. This paper describes the recent clinical experience with 213 Bi and 225 Ac. In view of the enormous benefit of targeted cancer treatment with alpha emitters, their production will have to be considerably increased beyond current supply capabilities. Alternative production methods based on the irradiation of uranium, thorium or radium targets at reactors or accelerator facilities have the potential to meet future demand.

中文翻译：

---

使用 bismuth-213 和 actinium-225 进行靶向 α 疗法：满足未来需求

靶向α疗法（TAT）是一种很有前景的癌症治疗方法。与传统疗法相比，使用 α 发射体进行癌症治疗具有两个明显的优势。人体组织中的短程 α 辐射（< 0.1 毫米）仅对应于几个细胞直径，可以选择性杀死靶向癌细胞，同时保护周围的健康组织。同时，α 辐射的高能量（几个 MeV）及其相关的高线性能量转移导致高效的细胞杀伤。因此，α 辐射可以破坏对 β 或 γ 辐射或化疗药物表现出抗性的细胞，因此可以为对常规疗法有抗性的肿瘤提供治疗选择。最近的结果证明了 α 发射体在治疗各种癌症方面的显着疗效，强调了 TAT 的临床潜力。本文描述了最近使用 213 Bi 和 225 Ac 的临床经验。鉴于使用 α 发射器进行靶向癌症治疗的巨大好处，它们的产量必须大大增加，超出目前的供应能力。基于在反应堆或加速器设施中对铀、钍或镭靶进行辐照的替代生产方法有可能满足未来的需求。它们的产量必须大大增加，超出目前的供应能力。基于在反应堆或加速器设施中对铀、钍或镭靶进行辐照的替代生产方法有可能满足未来的需求。它们的产量必须大大增加，超出目前的供应能力。基于在反应堆或加速器设施中对铀、钍或镭靶进行辐照的替代生产方法有可能满足未来的需求。